PMF most commonly stands for primary myelofibrosis, a rare blood cancer in which scar tissue gradually replaces healthy bone marrow. It affects roughly 0.4 to 1.5 people per 100,000 each year. In other contexts, PMF can refer to a probability mass function in statistics or progressive massive fibrosis, a severe occupational lung disease. This article covers all three meanings, starting with the most searched.
Primary Myelofibrosis: A Bone Marrow Cancer
Primary myelofibrosis is a cancer that starts in blood-forming stem cells deep inside your bone marrow. Normally, these stem cells produce red blood cells, white blood cells, and platelets in a balanced way. In PMF, a genetic mutation causes the stem cells to behave abnormally, triggering chronic inflammation and the buildup of tough, fibrous scar tissue (mostly reticulin and collagen fibers) inside the marrow. Over time, this scarring crowds out healthy blood cell production.
Because the marrow can no longer do its job efficiently, the body compensates. The spleen and liver try to pick up blood cell production, which causes them to swell, sometimes dramatically. An enlarged spleen is one of the hallmark signs of the disease. PMF can also develop as a secondary condition in people who already have a related blood disorder like polycythemia vera or essential thrombocythemia, but when it arises on its own, it’s called “primary.”
What Drives the Disease
About 90% of people with PMF carry a mutation in one of three genes. The JAK2 mutation is by far the most common, found in 60 to 65% of patients. CALR mutations account for 20 to 25%, and MPL mutations appear in roughly 5%. These mutations all hyperactivate the same signaling pathway inside cells, essentially keeping growth signals stuck in the “on” position. The remaining patients who lack all three mutations are sometimes called “triple negative,” and their disease tends to carry a worse prognosis.
The mutated stem cells don’t just grow unchecked. They also flood the bone marrow environment with inflammatory signals. One of these, a protein called TGF-beta, is a powerful trigger for fibroblasts, the cells that lay down scar tissue. Another inflammatory molecule, lipocalin-2, is markedly elevated in PMF patients and actually promotes the survival of cancerous stem cells while damaging normal ones. Enzymes that cross-link collagen further stabilize the scar tissue, making the fibrosis progressively harder to reverse.
Symptoms and How They Feel
PMF often develops slowly, and some people have no symptoms at the time of diagnosis. When symptoms do appear, they tend to fall into two categories: problems caused by low blood counts and problems caused by an enlarged spleen.
- Fatigue and weakness from anemia, often the first and most persistent complaint
- Shortness of breath during routine activities
- Pain or fullness below the left ribs from an enlarged spleen pressing on surrounding organs
- Early satiety, feeling full after eating very little, because the swollen spleen compresses the stomach
- Easy bruising and bleeding from low or dysfunctional platelets
- Bone pain, particularly in the legs and hips
- Fever and night sweats driven by the chronic inflammatory state
These so-called constitutional symptoms (fatigue, fevers, weight loss, night sweats) can be debilitating and significantly affect quality of life, even when blood counts look only mildly abnormal.
How PMF Is Diagnosed
Diagnosis requires a bone marrow biopsy. Under the microscope, pathologists look for abnormal platelet-producing cells (megakaryocytes) and grade the amount of fibrosis on a scale from 0 to 3. The World Health Organization recognizes two stages: prefibrotic (early) PMF, where scarring is minimal, and overt PMF, where fibrosis has reached grade 2 or 3.
To confirm the diagnosis, doctors need to meet three major criteria: characteristic bone marrow changes, the presence of a known driver mutation (JAK2, CALR, or MPL), and ruling out other blood cancers that can look similar. At least one minor criterion must also be present, such as anemia, an elevated white blood cell count, a palpable spleen, or elevated levels of an enzyme called LDH in the blood. These minor criteria need to be confirmed on two separate blood tests, not just one.
Prognosis and Risk Levels
Survival varies widely depending on when PMF is caught and how aggressive it is. Patients diagnosed in the early, prefibrotic phase can live 10 to 15 years or more. Those diagnosed when fibrosis is already advanced have a median survival of 3 to 7 years. Doctors use scoring systems that combine factors like age, hemoglobin level, white blood cell count, platelet count, the presence of certain chromosomal abnormalities, and whether a patient needs blood transfusions to assign a risk category: low, intermediate-1, intermediate-2, or high.
One of the most serious complications is transformation to acute myeloid leukemia, an aggressive blood cancer. This happens in roughly 20% of PMF patients over a 10-year period, a rate significantly higher than in related blood disorders. Transformation sometimes follows a recognizable acceleration phase with rising blast counts in the blood, though it can also occur abruptly.
Treatment Options
The only potentially curative treatment for PMF is an allogeneic stem cell transplant, which replaces the diseased marrow with healthy donor cells. This option carries significant risks and is typically reserved for younger patients with high-risk disease.
For most people, treatment focuses on controlling symptoms. JAK inhibitors are the primary drug class used. These medications work by blocking the overactive JAK-STAT signaling pathway that drives the disease. They are particularly effective at shrinking the spleen and reducing constitutional symptoms like night sweats and weight loss. Multiple JAK inhibitors are now approved, including options specifically designed for patients whose platelet counts are too low for older treatments. Your doctor will choose based on your blood counts, risk level, and overall health.
Supportive care, including blood transfusions for severe anemia, plays a role for many patients throughout the course of the disease.
PMF in Statistics: Probability Mass Function
In mathematics and statistics, PMF stands for probability mass function. It applies to discrete random variables, meaning variables that take on countable values like the number of heads in 10 coin flips or the result of rolling a die. The PMF assigns a probability to each possible outcome. Formally, for a random variable X, the PMF is written as p(x) = P(X = x), which simply means “the probability that X equals a specific value x.” Every valid PMF has two rules: each probability must be between 0 and 1, and all probabilities must add up to exactly 1.
If you are studying statistics, the PMF is the discrete counterpart to the probability density function (PDF), which applies to continuous variables like height or temperature. The distinction matters because you can read actual probabilities directly off a PMF, whereas a PDF requires calculating the area under a curve.
PMF in Occupational Medicine: Progressive Massive Fibrosis
Progressive massive fibrosis is the most severe stage of certain dust-related lung diseases, particularly coal workers’ pneumoconiosis (black lung) and chronic silicosis. It is defined by the formation of large scar tissue masses in the lungs, each at least one centimeter in diameter, visible on chest imaging. Key risk factors include heavy, prolonged exposure to coal mine dust or crystalline silica, the presence of earlier-stage small opacity disease, and a history of tuberculosis.
On chest X-rays, the large opacities of progressive massive fibrosis can be mistaken for lung cancer, tuberculosis, or other infections. MRI shows promise in telling them apart. Unlike the bone marrow condition, this form of PMF is entirely preventable through workplace dust control measures, though it remains a serious and sometimes fatal diagnosis for affected workers.